US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5977307A
(en)
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
WO1991004014A1
(en)
|
1989-09-21 |
1991-04-04 |
Synergen, Inc. |
Method for transporting compositions across the blood brain barrier
|
EP0517768A1
(en)
|
1990-02-28 |
1992-12-16 |
Schering Corporation |
Mammalian expression vectors
|
AU654811B2
(en)
|
1990-03-20 |
1994-11-24 |
Trustees Of Columbia University In The City Of New York, The |
Chimeric antibodies with receptor binding ligands in place of their constant region
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
JPH04166089A
(ja)
*
|
1990-10-30 |
1992-06-11 |
Eiken Chem Co Ltd |
免疫グロブリン遺伝子発現用プラスミドベクター、及びそれを用いてv領域の遺伝子を組換える方法
|
US5198340A
(en)
|
1991-01-17 |
1993-03-30 |
Genentech, Inc. |
Assay for free igf-i, igf-ii, and gh levels in body fluids
|
US5262308A
(en)
|
1992-01-28 |
1993-11-16 |
Thomas Jefferson University |
Cell lines which constitutively express IGF-1 and IGF-1 R
|
ATE191853T1
(de)
|
1992-07-27 |
2000-05-15 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
JPH08508409A
(ja)
|
1993-04-06 |
1996-09-10 |
シーダーズ − サイナイ メディカル センター |
変異インスリン様増殖因子▲i▼受容体サブユニットおよびそれらの使用方法
|
US20020022023A1
(en)
|
1999-01-15 |
2002-02-21 |
Axel Ullrich |
Treatment of diabetes mellitus and insulin receptor signal transduction
|
CN1241944C
(zh)
*
|
1995-09-11 |
2006-02-15 |
协和发酵工业株式会社 |
抗人白介素-5受体α链的抗体
|
US6084085A
(en)
|
1995-11-14 |
2000-07-04 |
Thomas Jefferson University |
Inducing resistance to tumor growth with soluble IGF-1 receptor
|
US6346390B1
(en)
|
1996-03-08 |
2002-02-12 |
Receptron, Inc. |
Receptor derived peptides involved in modulation of response to ligand binding
|
US5958872A
(en)
|
1996-04-01 |
1999-09-28 |
Apoptosis Technology, Inc. |
Active survival domains of IGF-IR and methods of use
|
US20020187925A1
(en)
|
1996-05-22 |
2002-12-12 |
Kingston David J. |
Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
|
AUPN999096A0
(en)
|
1996-05-22 |
1996-06-13 |
Northstar Biologicals Pty Ltd |
Peptides, antibodies, vaccines & uses thereof
|
US20020155095A1
(en)
|
1996-10-18 |
2002-10-24 |
Tattanahalli L. Nagabhushan |
Methods and compositions for delivery and expression of interferon-a nucleic acids
|
AU4808097A
(en)
|
1996-10-18 |
1998-05-15 |
Canji, Inc. |
Methods and compositions for delivery and expression of interferon-alpha nucleic acids
|
WO1998022092A1
(en)
|
1996-11-22 |
1998-05-28 |
The Regents Of The University Of California |
Transport of liposomes across the blood-brain barrier
|
US6399789B1
(en)
*
|
1996-12-18 |
2002-06-04 |
Kosan Biosciences, Inc. |
Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides
|
US6294330B1
(en)
|
1997-01-31 |
2001-09-25 |
Odyssey Pharmaceuticals Inc. |
Protein fragment complementation assays for the detection of biological or drug interactions
|
TW562807B
(en)
*
|
1997-04-01 |
2003-11-21 |
Chugai Pharmaceutical Co Ltd |
Novel secretory membrane protein
|
US6121416A
(en)
|
1997-04-04 |
2000-09-19 |
Genentech, Inc. |
Insulin-like growth factor agonist molecules
|
JPH1132779A
(ja)
*
|
1997-07-24 |
1999-02-09 |
Fujita Gakuen |
蛋白質の遺伝子クローニング法
|
IL136113A0
(en)
|
1997-11-14 |
2001-05-20 |
Euro Celtique Sa |
Modified antibodies with enhanced ability to elicit an anti-idiotype response
|
WO1999028347A1
(en)
|
1997-11-27 |
1999-06-10 |
Commonwealth Scientific And Industrial Research Organisation |
Method of designing agonists and antagonists to igf receptor
|
CA2322200A1
(en)
|
1998-02-24 |
1999-08-26 |
Receptron, Inc. |
Receptor derived peptides as modulators of receptor activity
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
CA2332331A1
(en)
|
1998-05-15 |
1999-11-25 |
Francisco Robert |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
US7173005B2
(en)
|
1998-09-02 |
2007-02-06 |
Antyra Inc. |
Insulin and IGF-1 receptor agonists and antagonists
|
US6875741B2
(en)
|
1998-09-02 |
2005-04-05 |
Renuka Pillutla |
Insulin and IGF-1 receptor agonists and antagonists
|
US20030236190A1
(en)
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
EP1953229A3
(en)
|
1998-10-15 |
2008-12-24 |
Novartis Vaccines and Diagnostics, Inc. |
Metastatic breast and colon cancer regulated genes
|
AU3579200A
(en)
|
1999-02-26 |
2000-09-14 |
Saltech I Goteborg Ab |
Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
|
US6316462B1
(en)
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
US6511967B1
(en)
*
|
1999-04-23 |
2003-01-28 |
The General Hospital Corporation |
Use of an internalizing transferrin receptor to image transgene expression
|
WO2000069454A1
(en)
|
1999-05-17 |
2000-11-23 |
Board Of Regents, The University Of Texas System |
Suppression of endogenous igfbp-2 to inhibit cancer
|
WO2001007084A1
(en)
|
1999-07-23 |
2001-02-01 |
Regents Of The University Of California |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
|
AU1339701A
(en)
|
1999-10-22 |
2001-05-08 |
Lifespan Biosciences, Inc. |
Anti-cancer nucleic acid and protein targets
|
EP2278021A3
(en)
*
|
1999-11-01 |
2011-05-18 |
Novartis Vaccines and Diagnostics, Inc. |
Expression vectors, transfection systems, and method of use thereof
|
AU1410801A
(en)
|
1999-11-17 |
2001-05-30 |
Compugen Ltd. |
Variants of alternative splicing
|
WO2001044464A1
(en)
|
1999-12-15 |
2001-06-21 |
Mcgill University |
Targeting of endosomal growth factor processing as anti-cancer therapy
|
AU2001245888A1
(en)
|
2000-03-21 |
2001-10-03 |
University Of South Florida |
Growth factor binding molecules
|
EP1265635A1
(en)
|
2000-03-22 |
2002-12-18 |
Glaxo Group Limited |
Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
|
TWI310684B
(en)
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
CA2402780A1
(en)
|
2000-03-29 |
2001-10-04 |
Dgi Biotechnologies, L.L.C. |
Insulin and igf-1 receptor agonists and antagonists
|
AU5521401A
(en)
|
2000-03-31 |
2001-10-15 |
Hyseq Inc |
Method and materials relating to insulin-like growth factor binding protein-likepolypeptides and polynucleotides
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
GB0012233D0
(en)
|
2000-05-19 |
2000-07-12 |
Devgen Nv |
Vector constructs
|
US7329745B2
(en)
|
2000-06-13 |
2008-02-12 |
City Of Hope |
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
|
US20030165502A1
(en)
|
2000-06-13 |
2003-09-04 |
City Of Hope |
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
|
WO2002004522A2
(en)
|
2000-07-10 |
2002-01-17 |
Novartis Ag |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
US20020164333A1
(en)
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
WO2002007783A2
(en)
|
2000-07-20 |
2002-01-31 |
Regents Of The University Of Minnesota |
Radiolabeled immunotoxins
|
KR100408844B1
(ko)
*
|
2000-07-29 |
2003-12-06 |
한국산업기술평가원 |
동물세포 발현벡터
|
US20030162230A1
(en)
|
2000-09-27 |
2003-08-28 |
Reagan Kevin J. |
Method for quantifying phosphokinase activity on proteins
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
DE10050338A1
(de)
|
2000-10-11 |
2002-04-25 |
Deutsches Krebsforsch |
Auf dem Nachweis von IGF-IRbeta und IRS-1 beruhendes Diagnose- bzw. Klassifizierungsverfahren für Carcinome
|
MXPA03003207A
(es)
|
2000-10-12 |
2004-03-26 |
Icos Corp |
Materiales y metodos para modular la actividad de union de ligando/enzimatica de proteinas alfa/¦ que contienen un sitio regulador alosterico.
|
EP1332368A2
(en)
|
2000-11-03 |
2003-08-06 |
Board of Regents, The University of Texas System |
Methods for detecting the efficacy of anticancer treatments
|
JP2004517078A
(ja)
|
2000-12-01 |
2004-06-10 |
シェーリング コーポレイション |
哺乳動物遺伝子および関連試薬の使用
|
DE60140074D1
(de)
|
2000-12-14 |
2009-11-12 |
Burnham Inst |
Non-apoptotische formen des zelltods und verfahren zur modulation
|
HUP0302525A2
(hu)
|
2001-01-05 |
2003-10-28 |
Abgenix, Inc. |
Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
|
ATE437233T1
(de)
|
2001-01-26 |
2009-08-15 |
Selexis Sa |
Matrix-anheftungsregionen und verfahren zu deren verwendung
|
EP1401476A4
(en)
|
2001-03-14 |
2006-03-08 |
Genentech Inc |
IGF ANTAGONIST PEPTIDES
|
FR2824076B1
(fr)
|
2001-04-27 |
2003-06-13 |
Centre Nat Rech Scient |
Methode de detection de composes activateurs ou inhibiteurs des recepteurs de la famille du recepteur de l'insuline au moyen d'un recepteur chimere isole
|
US20040116330A1
(en)
|
2001-04-27 |
2004-06-17 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
US7498029B2
(en)
|
2001-05-01 |
2009-03-03 |
The General Hospital Corporation |
Photoimmunotherapies for cancer using combination therapies
|
TWI238824B
(en)
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
WO2002102854A2
(en)
|
2001-06-20 |
2002-12-27 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
JP2005500833A
(ja)
|
2001-06-25 |
2005-01-13 |
ブアズーボ・アンパルトセルスカブ |
腫瘍学薬物の革新
|
US20040253635A1
(en)
|
2001-08-06 |
2004-12-16 |
Sylvie Luria |
Methods of identifying functional analogs of peptide regulators of biological pathways
|
AUPR870501A0
(en)
|
2001-11-07 |
2001-11-29 |
Biotech Research Ventures Pte Limited |
Composition containing a flavonoid glycone and method for using same as anti-proliferative
|
FR2834990A1
(fr)
|
2002-01-18 |
2003-07-25 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
US7553485B2
(en)
|
2002-01-18 |
2009-06-30 |
Pierre Fabre Medicament |
Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
FR2834900B1
(fr)
|
2002-01-18 |
2005-07-01 |
Pf Medicament |
Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
|
FR2834991B1
(fr)
|
2002-01-18 |
2004-12-31 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
CA2473039C
(fr)
|
2002-01-18 |
2014-09-23 |
Pierre Fabre Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
AU2003223661A1
(en)
|
2002-04-15 |
2003-11-03 |
Rigel Pharmaceuticals, Inc. |
Methods of assaying for cell cycle modulators
|
US7655397B2
(en)
|
2002-04-25 |
2010-02-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
|
US7485314B2
(en)
|
2002-05-06 |
2009-02-03 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Induction of antigen specific immunologic tolerance
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
GB0212303D0
(en)
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
WO2004007673A2
(en)
|
2002-07-12 |
2004-01-22 |
The Johns Hopkins University |
Neuronal gene expression patterns
|
US20040142381A1
(en)
|
2002-07-31 |
2004-07-22 |
Hubbard Stevan R. |
Methods for designing IGF1 receptor modulators for therapeutics
|
US20040047835A1
(en)
|
2002-09-06 |
2004-03-11 |
Cell Therapeutics, Inc. |
Combinatorial drug therapy using polymer drug conjugates
|
US20030138430A1
(en)
|
2002-09-20 |
2003-07-24 |
Stimmel Julie Beth |
Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
|
TW200501960A
(en)
|
2002-10-02 |
2005-01-16 |
Bristol Myers Squibb Co |
Synergistic kits and compositions for treating cancer
|
US20040102360A1
(en)
|
2002-10-30 |
2004-05-27 |
Barnett Stanley F. |
Combination therapy
|
US20060281130A1
(en)
|
2002-12-20 |
2006-12-14 |
Elisabeth Bock |
Metod of modulation of interaction between receptor and ligand
|
MXPA05008617A
(es)
|
2003-02-13 |
2005-11-04 |
Pfizer Prod Inc |
Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
|
BRPI0408317A
(pt)
|
2003-03-14 |
2006-03-07 |
Pharmacia Corp |
anticorpos do receptor de igf-i para o tratamento de cáncer
|
JP4473257B2
(ja)
|
2003-04-02 |
2010-06-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
インスリン様成長因子i受容体に対する抗体及びその使用
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
EP1622942B1
(en)
|
2003-05-01 |
2014-11-19 |
ImClone LLC |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
US7579157B2
(en)
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
MXPA06001634A
(es)
|
2003-08-13 |
2006-04-28 |
Pfizer Prod Inc |
Anticuerpos humanos modificados igf-1r.
|
DE10348391B3
(de)
|
2003-10-17 |
2004-12-23 |
Beru Ag |
Verfahren zum Glühen einer Glühkerze für einen Dieselmotor
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
EP1796711A2
(en)
|
2004-04-22 |
2007-06-20 |
Oregon Health and Science University |
Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
|
WO2005117980A1
(en)
|
2004-06-04 |
2005-12-15 |
Pfizer Products Inc. |
Method for treating abnormal cell growth
|
EP1802341A1
(en)
|
2004-07-16 |
2007-07-04 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
WO2007093008A1
(en)
|
2006-02-17 |
2007-08-23 |
Adelaide Research & Innovation Pty Ltd |
Antibodies to insulin-like growth factor i receptor
|